Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses.

Authors

Mamta Gupta, Hoon Choi, Thomas Karasic, Emma E Furth, Sydney Shaffer, Sarah Englander, Stephen Pickup, Cynthia Clendenin, Fang Liu, Quy Cao, Hee Kwon Song, Yong Fan, Jeffrey Duda, James C Gee, Mark Rosen, Peter J O'Dwyer, Rong Zhou

Published in

Cancer research communications. Aug 10, 2026. Epub Aug 10, 2026.

Abstract

A pilot clinical trial (NCT03519308) was conducted to evaluate perioperative chemotherapy (nab-paclitaxel, gemcitabine, and cisplatin; NGC) plus nivolumab, with or without synthetic vitamin D (paricalcitol) in resectable pancreatic ductal adenocarcinoma (PDAC). Preclinical studies were designed with statistical power to match the clinical trial treatment and compare NGC only versus NGC plus synthetic vitamin D (calcipotriol) or losartan (an antihypertensive medication).
Molecular subtyping was applied to enroll patients with epithelial subtype PDAC. Genetically engineered PDAC model (KPC mice, N=140) were randomized to NGC only and combined therapies. Multiparametric MRI and molecular profiling were integrated to assess treatment-induced effects on stroma, including capillary perfusion and density, matrix collagen content, fibroblast activation protein (FAP) level and transcriptome changes.
The clinical trial had limited enrollment (N=3) but confirmed the safety and feasibility of weekly paricalcitol infusion in combination with multiagent chemotherapy. NGC chemotherapy had a profound impact on stroma, inducing a remarkable reduction in FAP level accompanied by a significant increase in matrix collagen content; chemotherapy also activated epithelial mesenchymal transition and reduced blood perfusion and capillary density significantly, resulting in features of chemoresistance. Combining NGC with stromal-targeting agents-Calcipotriol or Losartan- diminished epithelial-to-mesenchymal transition and partially restored perfusion through distinct mechanisms: Calcipotriol activates vitamin D receptor to reprise a quiescent stroma while Losartan suppresses TGFβ to increase lymphocyte infiltration.
These findings support further investigations of stromal-directed combination strategies to overcome chemotherapy-induced resistance of PDAC. DCE-MRI may provide a valuable platform to monitor stromal adaptations to therapy in vivo.

PMID:
42574460
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.